A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas

Phase 1 Completed 22 enrolled Hoffmann-La Roche University of Pennsylvania · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study aims to seek evidence that activation of certain cells of the immune system will be safe and well tolerated in combination with cytotoxic chemotherapy. Preliminary evidence of clinical anti-tumor activity will be sought.

Timeline

Start: 2008-06
Primary completion: 2011-01
Completion: 2011-01

Publications

Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011 Mar 25;331(6024):1612-6. doi: 10.1126/science.1198443.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Selicrelumab	Monoclonal antibody	—	Intravenous
Background	Gemcitabine	Small molecule	1000 mg/m2	Intravenous

A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas

Summary

Timeline

Publications

Drugs

Indications